Epizyme, Inc. is a Cambridge, MA-based development-stage biopharmaceutical company focused on bringing novel epigenetic oncology therapies to the market.
Being a development-stage company, Epizyme does not have any approved product in its portfolio yet. Hence, investor focus should remain on pipeline updates.
Epizyme’s lead candidate, tazemetostat (an EZH2 inhibitor) is being evaluated in phase II studies in non-Hodgkin lymphoma (NHL) and genetically defined solid tumors. The company is also exploring tazemetostat to increase the clinical activity of immuno-oncology therapies by combining with an anti-PD 1 or PDL-1 agent.
The company’s track record has been strong, with the company beating estimates in each of the last four quarters, with an average positive earnings surprise of 11.96%.
Currently, Epizyme has a Zacks Rank # 3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Epizyme posted narrower-than-expected loss in the first quarter of 2017. While our consensus called for a loss of 63 cents per share, the company reported a loss of 56 cents.
Revenues:The company generated no revenues compared to the Zacks Consensus Estimate of 0.49 million.
Pipeline Update: The company said that it has initiated sixth cohort in phase II NHL study of tazemetostat, in combination with prednisolone in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The company also completed enrolment in all wild-type EZH2 cohorts in the phase II study of tazemetostat in patients with relapsed or refractory follicular lymphoma (FL) and DLBCL.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on EPZM earnings report later!
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>
Image: Bigstock
Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss
Epizyme, Inc. is a Cambridge, MA-based development-stage biopharmaceutical company focused on bringing novel epigenetic oncology therapies to the market.
Being a development-stage company, Epizyme does not have any approved product in its portfolio yet. Hence, investor focus should remain on pipeline updates.
Epizyme’s lead candidate, tazemetostat (an EZH2 inhibitor) is being evaluated in phase II studies in non-Hodgkin lymphoma (NHL) and genetically defined solid tumors. The company is also exploring tazemetostat to increase the clinical activity of immuno-oncology therapies by combining with an anti-PD 1 or PDL-1 agent.
The company’s track record has been strong, with the company beating estimates in each of the last four quarters, with an average positive earnings surprise of 11.96%.
Currently, Epizyme has a Zacks Rank # 3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Epizyme posted narrower-than-expected loss in the first quarter of 2017. While our consensus called for a loss of 63 cents per share, the company reported a loss of 56 cents.
Revenues:The company generated no revenues compared to the Zacks Consensus Estimate of 0.49 million.
Epizyme, Inc. Price and EPS Surprise
Epizyme, Inc. Price and EPS Surprise | Epizyme, Inc. Quote
Pipeline Update: The company said that it has initiated sixth cohort in phase II NHL study of tazemetostat, in combination with prednisolone in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The company also completed enrolment in all wild-type EZH2 cohorts in the phase II study of tazemetostat in patients with relapsed or refractory follicular lymphoma (FL) and DLBCL.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on EPZM earnings report later!
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>